Controlled Trial of Valacyclovir in Infectious Mononucleosis

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
University of Minnesota
Study ID
NCT00274404
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Infectious Mononucleosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis (mono) while being a safe drug. Because EBV is the cause of mono, it is expected that reduction of the amount of virus could result in faster recovery from the disease.

Key Dates

Start date
Feb 29, 2004
Status verified
Oct 2011
Primary completion
Sep 30, 2005
Completion
Sep 30, 2005

Study Design

Enrollment
20 participants
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Proportion of subjects who have at least a 100-fold (2log10) drop in the amount of EBV in their oral washes during the 14-day treatment period

Locations (1)

FacilityCityStateZIPSite coordinators
University of Minnesota Clinical Virology ClinicMinneapolisMinnesota55455-0392-

Find similar trials in Minneapolis, MN

By research site
University of Minnesota Clinical Virology Clinic· Minneapolis, MN

Related Studies